Genpharmasec Ltd

Genpharmasec Ltd has delivered a notably positive financial performance in the quarter ended June 2026, with net sales surging 42.1% compared to the previous four-quarter average and a higher PAT of ₹1.75 crores over the last six months. Despite this encouraging quarterly momentum, the company continues to face significant headwinds reflected in its long-term returns and a recent downgrade to a Strong Sell rating by MarketsMOJO.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 21 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 10 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Genpharmasec Limited, a micro-cap trading and distribution company with a market capitalisation of ₹68.00 crores, reported its fourth quarter results for FY26 (Mar'26) with a consolidated net profit of ₹1.23 crores, representing a dramatic decline of 555.56% year-on-year from a loss of ₹0.27 crores in Mar'25. Despite impressive top-line expansion with revenues surging 295.65% YoY to ₹55.43 crores, the company continues to grapple with profitability challenges and structural concerns that have kept its stock under pressure, currently trading at ₹1.22 after a modest 4.27% gain on result day.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Genpharmasec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Genpharmasec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 May 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 April 2026, providing investors with the latest comprehensive view of the company’s position.

For the second consecutive session, Genpharmasec Ltd has extended its decline, hitting a fresh 52-week low of Rs 0.79 on 30 Mar 2026, marking a 12.09% drop over two days amid broader market weakness.

Genpharmasec Ltd’s share price declined sharply to a new 52-week low of ₹0.88 on 27 March 2026, marking a significant downturn in the stock’s performance over the past year. This drop reflects ongoing challenges faced by the company within the Trading & Distributors sector, compounded by broader market weakness and deteriorating financial metrics.

Genpharmasec Ltd, a micro-cap player in the Trading & Distributors sector, has touched a new 52-week and all-time low of Rs.0.89 on 19 Mar 2026, marking a significant decline amid broader market weakness and sector underperformance.

Genpharmasec Ltd, a micro-cap player in the Trading & Distributors sector, has recorded a fresh 52-week and all-time low of Rs.0.91 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial and market performance.